BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

The Clearinghouse-II final rule will direct state licensing agencies to revoke the privileges of more than 170,000 commercial ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

Set to become compulsory Nov. 20, the regulation isn't likely to make pharma ads easier for consumers to comprehend, but ...

The second phase of FMCSA's Drug & Alcohol Clearinghouse takes effect Monday, Nov. 18, which requires states to downgrade ...

Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...

Against the backdrop of high medical costs and an imbalance of access to care, is there reason to be optimistic about the ...

Traip junior Keele Ford is winning awards for her sugar kelp sunscreen and hopes one day to gain approval to bring it to ...

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer ...

Autolus is ready to hit the ground running after winning FDA approval for its Aucatzyl ... U.K. site dubbed “the Nucleus” with Cardinal Health serving as the U.S. commercial distribution partner. The ...

FMCSA Clearinghouse Phase 2 enforcement may impact about 179,000 CDL holders who are in prohibited status for a drug or ...

Blueprint Medicines' AYVAKIT leads its revenue growth, while its pipeline targets multiple cancers. Read why BPMC stock is a ...